Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FFAR1 | O14842 | 2/20 | 0.54 |
| ▸ | NPC1 | O15118 | 2/20 | 0.53 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.53 |
| ▸ | RAB9A | P51151 | 2/20 | 0.53 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.53 |
| ▸ | RELA | Q04206 | 2/20 | 0.53 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.53 |
| ▸ | CES1 | P23141 | 3/20 | 0.50 |
| ▸ | MMP12 | P39900 | 1/20 | 0.49 |
| ▸ | FAAH | O00519 | 1/20 | 0.46 |
| ▸ | NCEH1 | Q6PIU2 | 1/20 | 0.46 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17080263 | 0.88 | HPGDS (0.49) | FFAR1NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL5801662 | 0.86 | FFAR1 (0.71) | FFAR1CES1MMP12 | |
| SCHEMBL19544482 | 0.82 | FFAR1 (0.50) | FFAR1NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL20426084 | 0.78 | RARB (0.53) | NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL11262500 | 0.77 | FFAR1 (0.63) | FFAR1NPC1RAB9ASMN1; SMN2MMP12 | |
| SCHEMBL7796725 | 0.77 | FFAR1 (0.54) | FFAR1NPC1RAB9ASMN1; SMN2 | |
| SCHEMBL17080177 | 0.76 | FFAR1 (0.44) | FFAR1CES1MMP12 | |
| SCHEMBL27396759 | 0.76 | HDAC2 (0.68) | FFAR1SMN1; SMN2MMP12 | |
| SCHEMBL19544320 | 0.76 | MMP12 (0.47) | FFAR1NPC1NFKB1RAB9ANFKB2 | |
| SCHEMBL5020712 | 0.75 | FFAR1 (0.69) | FFAR1SMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | RECEPTOS LLC | 2017-11-02 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170313717-A1 | NOVEL GLP-1 RECEPTOR MODULATORS | GLP1R, GIPR, NPY1R | FFAR1 104/4885NPC1 2943/4885NFKB1 3726/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.